Cost-effectiveness of highly active antiretroviral therapy in South Africa.

PubWeight™: 3.01‹?› | Rank: Top 1%

🔗 View Article (PMC 1298940)

Published in PLoS Med on December 06, 2005

Authors

Motasim Badri1, Gary Maartens, Sundhiya Mandalia, Linda-Gail Bekker, John R Penrod, Robert W Platt, Robin Wood, Eduard J Beck

Author Affiliations

1: Department of Medicine, Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa. motasim.badri@hiv-research.org.za

Articles citing this

Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25

Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science (2013) 5.01

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med (2008) 3.56

The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS (2011) 3.35

Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med (2008) 2.96

HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med (2012) 2.21

Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis (2008) 2.05

The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy (2009) 1.94

Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Med (2013) 1.73

The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS One (2011) 1.67

Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia. PLoS One (2012) 1.57

The determinants of HIV treatment costs in resource limited settings. PLoS One (2012) 1.47

Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting. J Int AIDS Soc (2010) 1.28

Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands. PLoS One (2008) 1.27

Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS (2011) 1.18

Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS One (2011) 1.16

Healthcare utilization of patients accessing an African national treatment program. BMC Health Serv Res (2007) 1.14

The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc (2008) 1.13

The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008. PLoS One (2011) 1.09

Treatment as prevention: preparing the way. J Int AIDS Soc (2011) 1.09

Cost estimates of HIV care and treatment with and without anti-retroviral therapy at Arba Minch Hospital in southern Ethiopia. Cost Eff Resour Alloc (2009) 1.06

Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med (2014) 1.03

Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis. J Acquir Immune Defic Syndr (2009) 0.99

The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean. J Acquir Immune Defic Syndr (2007) 0.98

Estimating the resources required in the roll-out of universal access to antiretroviral treatment in Zimbabwe. Sex Transm Infect (2011) 0.97

Rising population cost for treating people living with HIV in the UK, 1997-2013. PLoS One (2010) 0.96

Cost-effectiveness of antiretroviral therapy for prevention. Curr HIV Res (2011) 0.95

Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006. PLoS One (2011) 0.93

Early severe morbidity and resource utilization in South African adults on antiretroviral therapy. BMC Infect Dis (2009) 0.93

The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health Policy (2008) 0.92

Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens. PLoS Med (2008) 0.92

S4HARA: System for HIV/AIDS resource allocation. Cost Eff Resour Alloc (2008) 0.89

Challenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-associated tuberculosis. Clin Infect Dis (2013) 0.89

Is antiretroviral therapy cost-effective in South Africa? PLoS Med (2006) 0.88

A novel Markov model projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public clinics in South Africa. PLoS One (2013) 0.88

Projected economic evaluation of the national implementation of a hypothetical HIV vaccination program among adolescents in South Africa, 2012. BMC Public Health (2016) 0.88

Estimating the cost to rural ambulating HIV/AIDS patients on highly active antiretroviral therapy (HAART) in rural Ghana: a pilot study. Pan Afr Med J (2012) 0.85

The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis. PLoS Med (2015) 0.80

Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008. PLoS One (2012) 0.79

Cost-Effectiveness of Initiating Antiretroviral Therapy at Different Points in TB Treatment in HIV-TB Coinfected Ambulatory Patients in South Africa. J Acquir Immune Defic Syndr (2015) 0.78

Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia. Cost Eff Resour Alloc (2009) 0.77

The Case for Adolescent HIV Vaccination in South Africa: A Cost-Effectiveness Analysis. Medicine (Baltimore) (2016) 0.77

A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes. Clinicoecon Outcomes Res (2015) 0.76

The High Cost of HIV-Positive Inpatient Care at an Urban Hospital in Johannesburg, South Africa. PLoS One (2016) 0.75

The Social Determinants of Chronic Disease. Am J Prev Med (2017) 0.75

Articles cited by this

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54

The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med (2001) 5.89

Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet (2002) 5.80

Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (2003) 5.52

Discounting and health benefits. Health Econ (1992) 4.39

The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS (2002) 4.01

Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med (2001) 3.64

Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet (2001) 3.36

Interim proposal for a WHO Staging System for HIV infection and Disease. Wkly Epidemiol Rec (1990) 3.32

Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS (2004) 2.78

Impact of combination therapy for HIV infection on inpatient census. N Engl J Med (1997) 1.99

Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS (1999) 1.70

Admission trends in a rural South African hospital during the early years of the HIV epidemic. JAMA (1999) 1.65

The changing impact of HIV/AIDS on Kenyatta National Hospital, Nairobi from 1988/89 through 1992 to 1997. AIDS (2000) 1.58

Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med (2001) 1.55

The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS (2004) 1.27

Health service use and household expenditure during terminal illness due to AIDS in rural Tanzania. Trop Med Int Health (2002) 1.17

Bed occupancy due to HIV/AIDS in an urban hospital medical ward in Uganda. AIDS (1994) 1.14

Cost effectiveness of combination HIV therapy: 3 years later. Pharmacoeconomics (2000) 1.14

Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering Group. AIDS (1999) 1.12

The cost of HIV treatment and care. A global review. Pharmacoeconomics (2001) 1.09

Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa. S Afr Med J (2002) 1.08

AIDS and hospital bed occupancy: an overview. Trop Med Int Health (1997) 1.01

Changing use of hospital services and costs at a London AIDS referral centre, 1983-1989. AIDS (1994) 0.94

Changing presentation and survival, service utilization and costs for AIDS patients: insights from a London referral centre. AIDS (1994) 0.94

Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res (2002) 0.93

South Africa takes first steps to provide antiretrovirals. Bull World Health Organ (2002) 0.86

The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on Costs. Pharmacoeconomics (1998) 0.86

Effect of HAART on health status and hospital costs of severe HIV-infected patients: a modeling approach. HIV Clin Trials (2001) 0.85

The impact of HIV on resource utilization by patients with tuberculosis in a tertiary referral hospital, Nairobi, Kenya. Tuber Lung Dis (1993) 0.84

Articles by these authors

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06

Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25

Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS (2005) 11.25

Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS (2004) 11.18

Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis (2006) 9.25

Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology (2009) 9.00

Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS (2006) 7.49

Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis (2011) 7.23

Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS (2005) 6.83

Breastfeeding and child cognitive development: new evidence from a large randomized trial. Arch Gen Psychiatry (2008) 6.78

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73

Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis (2005) 6.59

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54

Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29

Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J (2006) 6.29

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med (2007) 6.26

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol (2009) 6.07

Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet (2010) 6.02

Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94

Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73

Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis (2006) 5.68

Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (2003) 5.52

Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS (2010) 5.46

Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS (2007) 5.41

Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41

Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis (2007) 5.32

Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med (2011) 5.06

Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr (2006) 4.81

Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS (2010) 4.68

Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS (2002) 4.42

When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31

Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29

Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS (2009) 4.29

Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med (2008) 4.12

Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 4.07

Effects of prolonged and exclusive breastfeeding on child height, weight, adiposity, and blood pressure at age 6.5 y: evidence from a large randomized trial. Am J Clin Nutr (2007) 3.96

High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis (2008) 3.92

Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS (2009) 3.91

Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis (2009) 3.77

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71

Reducing bias through directed acyclic graphs. BMC Med Res Methodol (2008) 3.67

Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (2007) 3.60

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med (2008) 3.56

Illustrating bias due to conditioning on a collider. Int J Epidemiol (2009) 3.54

Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One (2010) 3.48

Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr (2009) 3.41

CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39

Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS (2008) 3.31

Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. Arthritis Rheum (2002) 3.29

Fertility intentions and reproductive health care needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services. AIDS Behav (2009) 3.29

Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther (2007) 3.27

Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS (2005) 3.16

Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci U S A (2003) 3.14

Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10

Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05

Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01

Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health (2009) 2.99

Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J (2009) 2.97

Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS (2008) 2.96

Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96

AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS (2009) 2.92

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis (2005) 2.91

Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS (2010) 2.90

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther (2006) 2.85

Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS (2010) 2.83

Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med (2008) 2.82

National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS (2006) 2.82

Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med (2011) 2.80

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79

Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS (2004) 2.78

Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study. J Acquir Immune Defic Syndr (2006) 2.77

Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS (2009) 2.75

Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis (2011) 2.72

Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.72